<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 22, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02581163</url>
  </required_header>
  <id_info>
    <org_study_id>P15-650</org_study_id>
    <nct_id>NCT02581163</nct_id>
  </id_info>
  <brief_title>Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, +/- Dasabuvir, +/- Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium</brief_title>
  <official_title>Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, +/- Dasabuvir, +/- Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <authority>Belgium: Ethics Committee</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to provide evidence of the effectiveness as well as the influence of adherence
      on treatment outcome of Paritaprevir/ritonavir, Ombitasvir, +/- Dasabuvir, (the ABBVIE
      REGIMEN) ± Ribavirin (RBV) in a real world setting of hepatitis C virus infected clinical
      practice populations across Belgium. The study may also help identify predictive factors of
      response that are important in real world treatment settings. In addition, it will provide
      data on the impact of adherence on treatment outcomes in everyday settings, which may help
      treating physicians to improve the management of participants under their care.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Percentage of participants achieving sustained virological response at week 12 (SVR12)</measure>
    <time_frame>12 weeks after the last dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>SVR12 is defined as hepatitis c virus ribonucleic acid levels &lt;50 IU/mL 12 weeks after the last dose of study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with virological response.</measure>
    <time_frame>End of treatment (EoT), 12 or 24 weeks after first dose according to treatment schedule chosen by investigator.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Virologic response is defined as HCV RNA &lt;50 IU/ml.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who relapse</measure>
    <time_frame>At 12 and 24 weeks after last dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>Relapse is defined as HCV RNA &lt; 50 IU/ml at end of treatment followed by HCV RNA ≥ 50 IU/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who achieved breakthrough</measure>
    <time_frame>From baseline till End of treatment: 12 or 24 weeks after first dose according to treatment schedule chosen by investigator</time_frame>
    <safety_issue>No</safety_issue>
    <description>Breakthrough is defined as at least one documented HCV RNA &lt;50 IU/ml followed by HCV RNA ≥ 50 IU/ml during treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients meeting On-treatment virologic failure</measure>
    <time_frame>12 weeks after last dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>On-treatment virologic failure : breakthrough or failure to suppress [each measured on-treatment HCV RNA value ≥50 IU/mL]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients meeting relapse</measure>
    <time_frame>12 weeks after last dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>Relapse : defined as HCV RNA &lt;50 IU/mL at EoT or at the last on-treatment HCV RNA measurement followed by HCV RNA ≥50 IU/mL post-treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients meeting Premature study drug discontinuation with no on-treatment virologic failure</measure>
    <time_frame>12 weeks after last dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients missing SVR12 data and/or none of the above criteria</measure>
    <time_frame>12 weeks after last dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of the DAA dose taken in relation to the target dose of DAA</measure>
    <time_frame>From Baseline till EoT (12 or 24 weeks after first dose according to treatment schedule chosen by investigator)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Adherence : cumulative dose taken divided by target dose in percent</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of the RBV dose taken in relation to the target dose of RBV</measure>
    <time_frame>From Baseline till EoT (12 or 24 weeks after first dose according to treatment schedule chosen by investigator)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Adherence : cumulative dose taken divided by target dose in percent</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of missed RBV treatment days in relation to the target number of RBV treatment days</measure>
    <time_frame>From Baseline till EoT (12 or 24 weeks after first dose according to treatment schedule chosen by investigator)</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Chronic Hepatitis C, Genotype 1 or 4</condition>
  <arm_group>
    <arm_group_label>GT 1 or 4 treatment-naïve or -experienced CHC participants</arm_group_label>
    <description>Treatment-naïve or -experienced participants with confirmed CHC, genotype (GT) 1 or 4, receiving combination therapy with the interferon-free ABBVIE REGIMEN ± RBV according to standard of care and in line with the current local label</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Treatment-naïve or -experienced participants with confirmed CHC, genotype 1 or 4
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treatment-naïve or -experienced participants with confirmed CHC, genotype 1 or 4,
             receiving combination therapy with the interferon-free ABBVIE REGIMEN ± RBV according
             to standard of care and in line with the current local label

          -  If RBV is co-administered with the ABBVIE REGIMEN, it has been prescribed in line
             with the current local label (with special attention to contraception requirements
             and contraindication during pregnancy)

          -  Participants must sign and date an informed consent

        Exclusion Criteria:

        • Participant participating or intending to participate in a concurrent interventional
        therapeutic trial
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simonne Lens, MD</last_name>
    <role>Study Director</role>
    <affiliation>Be.medicalinformation@abbvie.com</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Simonne Lens, MD</last_name>
    <phone>0032 (0)10 477 811</phone>
    <email>Be.medicalinformation@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Van den Enden, MD</last_name>
    <phone>0032 (0)10 477 811</phone>
    <email>Be.medicalinformation@abbvie.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141787</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 141787, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141777</name>
      <address>
        <city>Antwerp</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 141777, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141766</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 141766, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141769</name>
      <address>
        <city>Brussels</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 141769, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141770</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 141770, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141771</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 141771, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141782</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 141782, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141784</name>
      <address>
        <city>Brussels</city>
        <zip>1180</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 141784, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 143078</name>
      <address>
        <city>Bruxelles</city>
        <zip>1190</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 143078, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141788</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 141788, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141768</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 141768, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141785</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 141785, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141775</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 141775, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141786</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 141786, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141783</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 141783, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141773</name>
      <address>
        <city>La Louviere</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 141773, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141772</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 141772, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141767</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 141767, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141776</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 141776, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141779</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 141779, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://rxabbvie.com</url>
  </link>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 19, 2015</lastchanged_date>
  <firstreceived_date>October 19, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Effectiveness</keyword>
  <keyword>Influence of adherence</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
